Refine Search
(12)
(13)
(13)
(14)

Cardiovascular Disease

The total revenue from branded cardiovascular drugs in 2017 is projected to be just over $40 billion. Top companies in this space are putting a heavy focus on the anti-thrombotic segment, as these drugs continue to bring in the biggest profit and dominate the cardiovascular market. Bayer currently holds the top spot in the market with 2017 sales of $5.4 billion; however, Sanofi and BMS come in a close second and third with sales of $5.1 and $4.7 billion, respectively.

Hypertrophic Cardiomyopathy - Pipeline Review, H1 2018

  • $2,000
  • April 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Hypertrophic Cardiomyopathy - Pipeline Review, H1 2018’, provides an overview of the Hypertrophic Cardiomyopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under develo...

Behcet Disease - Pipeline Review, H1 2018

  • $2,000
  • April 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Behcet Disease - Pipeline Review, H1 2018’, provides an overview of the Behcet Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Behcet Disease, ...

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2018

  • $2,000
  • April 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2018’, provides an overview of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline landscape.

The report provide...

Ventricular Tachycardia - Pipeline Review, H1 2018

  • $2,000
  • April 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Ventricular Tachycardia - Pipeline Review, H1 2018’, provides an overview of the Ventricular Tachycardia pipeline landscape.

The report provides comprehensive information on the therapeutics under development fo...

Atherosclerosis - Pipeline Review, H1 2018

  • $2,000
  • March 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Atherosclerosis - Pipeline Review, H1 2018’, provides an overview of the Atherosclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atherosclerosi...

Stroke - Pipeline Review, H1 2018

  • $2,000
  • March 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Stroke - Pipeline Review, H1 2018’, provides an overview of the Stroke pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Stroke, complete with analysis b...

Critical Limb Ischemia - Pipeline Review, H1 2018

  • $2,000
  • March 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Critical Limb Ischemia - Pipeline Review, H1 2018’, provides an overview of the Critical Limb Ischemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for ...

Angina (Angina Pectoris) - Pipeline Review, H1 2018

  • $2,000
  • March 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Angina (Angina Pectoris) - Pipeline Review, H1 2018’, provides an overview of the Angina (Angina Pectoris) pipeline landscape.

The report provides comprehensive information on the therapeutics under development ...

Arterial Thrombosis - Pipeline Review, H1 2018

  • $2,000
  • March 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Arterial Thrombosis - Pipeline Review, H1 2018’, provides an overview of the Arterial Thrombosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Arteri...

Myocardial Infarction - Pipeline Review, H1 2018

  • $2,000
  • February 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Myocardial Infarction - Pipeline Review, H1 2018’, provides an overview of the Myocardial Infarction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for My...

Pulmonary Arterial Hypertension - Pipeline Review, H1 2018

  • $2,000
  • February 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Pulmonary Arterial Hypertension - Pipeline Review, H1 2018’, provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics unde...

Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2018

  • $2,000
  • February 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Deep Vein Thrombosis (DVT) - Pipeline Review, H1 2018’, provides an overview of the Deep Vein Thrombosis (DVT) pipeline landscape.

The report provides comprehensive information on the therapeutics under developm...

Hypertension - Pipeline Review, H2 2017

  • $2,000
  • December 2017
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Hypertension - Pipeline Review, H2 2017’, provides an overview of the Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypertension, comple...

Septic Shock - Pipeline Review, H2 2016

  • $2,000
  • September 2016
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Septic Shock - Pipeline Review, H2 2016’, provides an overview of the Septic Shock pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Septic Shock, comple...